HEALTHCARE RESOURCE UTILIZATION WITH IXAZOMIB OR PLACEBO PLUS LENALIDOMIDE-DEXAMETHASONE IN THE RANDOMIZED, DOUBLE-BLIND, PHASE 3 TOURMALINE-MM1 STUDY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

被引：0
|
作者：
Hari, P. [1 ]
Lin, H. M. [2 ]
Zhu, Y. [2 ]
Berg, D. [2 ]
Richardson, P. [3 ]
Moreau, P. [4 ]
机构：
[1] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[2] Millennium Pharmaceut Inc, Cambridge, MA USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Univ Hosp Hotel Dieu, Nantes, France
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P735
引用
下载
收藏
页码：297 / 298
页数：2
相关论文
共 50 条
  • [1] Healthcare resource utilization with ixazomib or placebo plus lenalidomide-dexamethasone in the randomized, double-blind, phase 3 TOURMALINE-MM1 study in relapsed/refractory multiple myeloma
    Hari, Parameswaran
    Lin, Huamao Mark
    Zhu, Yanyan
    Berg, Deborah
    Richardson, Paul G.
    Moreau, Philippe
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (08) : 793 - 798
  • [2] IXAZOMIB PLUS LENALIDOMIDE-DEXAMETHASONE (IRD) VS PLACEBO-RD IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): CHINA CONTINUATION OF TOURMALINE-MM1
    Hou, J.
    Jin, J.
    Xu, Y.
    Wu, D.
    Ke, X.
    Daobin, Z.
    Lu, J.
    Du, X.
    Chen, X.
    Li, J.
    Liu, J.
    Wang, B.
    Zhang, X.
    Wang, H.
    van de Velde, H.
    Richardson, P.
    Moreau, P.
    HAEMATOLOGICA, 2016, 101 : 540 - 540
  • [3] Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study
    Hou, Jian
    Jin, Jie
    Xu, Yan
    Wu, Depei
    Ke, Xiaoyan
    Zhou, Daobin
    Lu, Jin
    Du, Xin
    Chen, Xiequn
    Li, Junmin
    Liu, Jing
    Gupta, Neeraj
    Hanley, Michael J.
    Li, Hongmei
    Hua, Zhaowei
    Wang, Bingxia
    Zhang, Xiaoquan
    Wang, Hui
    van de Velde, Helgi
    Richardson, Paul G.
    Moreau, Philippe
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2017, 10
  • [4] Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study
    Jian Hou
    Jie Jin
    Yan Xu
    Depei Wu
    Xiaoyan Ke
    Daobin Zhou
    Jin Lu
    Xin Du
    Xiequn Chen
    Junmin Li
    Jing Liu
    Neeraj Gupta
    Michael J. Hanley
    Hongmei Li
    Zhaowei Hua
    Bingxia Wang
    Xiaoquan Zhang
    Hui Wang
    Helgi van de Velde
    Paul G. Richardson
    Philippe Moreau
    Journal of Hematology & Oncology, 10
  • [5] Ixazomib plus lenalidomide-dexamethasone (IRd) vs placebo-Rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM): China continuation of TOURMALINE-MM1.
    Hou, Jian
    Jin, Jie
    Xu, Yan
    Wu, Depei
    Ke, Xiaoyan
    Zhou Daobin
    Lou, Jin
    Du, Xin
    Chen, Xiequn
    Li, Junmin
    Liu, Jing
    Wang, Bingxia
    Zhang, Xiaoquan
    Wang, Hui
    Van De Velde, Helgi
    Richardson, Paul G.
    Moreau, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] Improved PFS and OS With Ixazomib Plus Lenalidomide-Dexamethasone (IRd) vs Placebo-Rd in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM): Final Data From the Phase 3 China Continuation of TOURMALINE-MM1
    Hou, Jian
    Jin, Jie
    Xu, Yan
    Wu, Depei
    Ke, Xiaoyan
    Daobin, Zhou
    Lu, Jin
    Du, Xin
    Chen, Xiequn
    Li, Junmin
    Liu, Jing
    Gupta, Neeraj
    Hanley, Michael
    Li, Hongmei
    Hua, Zhaowei
    Wang, Bingxia
    Zhang, Xiaoquan
    Wang, Hui
    van de Velde, Helgi
    Richardson, Paul
    Moreau, Philippe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E67 - E67
  • [7] Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
    Richardson, Paul G.
    Kumar, Shaji K.
    Masszi, Tamas
    Grzasko, Norbert
    Bahlis, Nizar J.
    Hansson, Markus
    Pour, Ludek
    Sandhu, Irwindeep
    Ganly, Peter
    Baker, Bartrum W.
    Jackson, Sharon R.
    Stoppa, Anne-Marie
    Gimsing, Peter
    Garderet, Laurent
    Touzeau, Cyrille
    Buadi, Francis K.
    Laubach, Jacob P.
    Cavo, Michele
    Darif, Mohamed
    Labotka, Richard
    Berg, Deborah
    Moreau, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (22) : 2430 - +
  • [8] Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study
    Gupta, Neeraj
    Goh, Yeow Tee
    Min, Chang-Ki
    Lee, Jae Hoon
    Kim, Kihyun
    Wong, Raymond S. M.
    Chim, Chor Sang
    Hanley, Michael J.
    Yang, Huyuan
    Venkatakrishnan, Karthik
    Hui, Ai-Min
    Esseltine, Dixie-Lee
    Chng, Wee Joo
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2015, 8
  • [9] Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma
    Suzuki, Kenshi
    Handa, Hiroshi
    Chou, Takaaki
    Ishizawa, Kenichi
    Takubo, Takatoshi
    Kase, Yoichi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2017, 105 (04) : 445 - 452
  • [10] Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1
    Mateos, Maria-Victoria
    Masszi, Tamas
    Grzasko, Norbert
    Hansson, Markus
    Sandhu, Irwindeep
    Pour, Ludek
    Viterbo, Luisa
    Jackson, Sharon R.
    Stoppa, Anne-Marie
    Gimsing, Peter
    Hamadani, Mehdi
    Borsaru, Gabriela
    Berg, Deborah
    Lin, Jianchang
    Di Bacco, Alessandra
    van de Velde, Helgi
    Richardson, Paul G.
    Moreau, Philippe
    HAEMATOLOGICA, 2017, 102 (10) : 1767 - 1775
12345